Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Duodenal Neoplasms 1Colorectal Neoplasms 1Barrett Esophagus 1Attenuated familial adenomatous polyposis 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 67Radiotherapy 53Cisplatin 52Oxaliplatin 47Leucovorin 37Paclitaxel 36Irinotecan 27Docetaxel 23Capecitabine 20Nivolumab 16Carboplatin 16pembrolizumab 15Radiation 15Neoadjuvant Therapy 15Surgical Procedures, Operative 12Cetuximab 12durvalumab 9Taxes 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Trastuzumab 7Magnetic Resonance Spectroscopy 7Gefitinib 7tremelimumab 6Endoscopy, Digestive System 6Endoscopy 6Biopsy 6Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma Of Esophagus × obeticholic acid × Clear all
NCT04939051 2026-05-13

Obeticholic Acid for Prevention in Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡